Heated chemo combo tested in abdominal cancer surgery
NCT ID NCT01226550
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a treatment for peritoneal carcinosis, a cancer that has spread to the lining of the abdomen from the stomach, bowel, or appendix. The approach combined surgery to remove visible tumors with heated chemotherapy drugs (mitomycin C and irinotecan) pumped directly into the abdomen during the operation. The trial enrolled 18 people and focused on finding safe drug doses and tracking side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mitomycin C and irinotecan (chemotherapy drugs)
- What this could lead to
- If this approach proves safe and effective, it could offer a treatment option for people with peritoneal cancer that has spread from the digestive system.
- What could go wrong
- This was a very small, early-phase study (18 people) focused on safety and dosing, not on curing the disease. The combination of major surgery and heated chemotherapy carries significant risks, including serious complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERITONEAL CARCINOSIS (PC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Chirurgie Générale et Thoracique, Centre Hospitalier Lyon-Sud
Pierre-Bénite, 69495, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Abdominal chemotherapy after surgery may improve mesothelioma outcomes
- New combo therapy targets rare abdominal cancer
- Lab-Grown tumor models could personalize mesothelioma care
- New drug combo targets Hard-to-Treat cancers with genetic weakness
- New immunotherapy combo targets rare cancers left behind by progress
- Immunotherapy boosts standard chemo in rare abdominal cancer trial